June Laffey was appointed to the new position of Executive Vice President, Chief Creative Officer, McCann Health New York.
Illegal shipments of the powerful and addictive opioid fentanyl are pouring into the United States by mail from China.
Spark Therapeutics licensed rights to its breakthrough gene therapy Luxturna outside the United States to Switzerland-based Novartis.
The use of artificial intelligence to address health concerns is a growing field and tech giant Google is backing Chinese company XtalPi Inc. in its goal of using AI to help with drug design.
The biopharma industry is perceived to be at a turning point, where companies have the opportunity to meaningfully adapt their innovation strategy and take advantage of major technological advances and new therapeutic modalities.
Philanthropist Bill Gates’ fund is aimed at wiping out the disease in seven of the region’s countries and the Dominican Republic.
A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in the future.
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.
Puma Biotechnology Inc. said a European regulatory panel indicated it was unlikely to provide a positive opinion on the company’s breast cancer drug.
McCann Health announced the appointment of Linda Szyper to the new position of Global Chief Operating Officer.
A U.S. appeals court upheld a ruling that invalidated a crucial J&J patent on its blockbuster rheumatoid arthritis drug Remicade.
Tmunity Therapeutics closed on a Series A financing worth $100 million. Syndicate investors included Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, and Be The Match BioTherapies.
Rhode Island-based MindImmune Therapeutics forged a research agreement with Pfizer to develop treatments for a number of CNS disorders.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage clinical trials.
Drugmakers’ response to the threat posed by “superbugs” remains patchy even after years of warnings, according to the first analysis of individual companies’ efforts to tackle the antibiotic resistance crisis.
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency Versus Other Amyloid Beta-Directed Antibodies
ProMis Neurosciences Inc. reported further results of its previously announced and ongoing preclinical program for Alzheimer’s disease.
Johnson & Johnson said it would take a $13.6 billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.
CDC Director Dr. Brenda Fitzgerald urged Americans to get flu shots amid one of the most severe flu seasons in years.
Paris, France-based Sanofi announced major restructuring involving layoffs. About 400 jobs cut will be in the U.S.
Celgene Corp. announced a $9 billion cash buyout of Juno Therapeutics Inc. as the Summit, N.J.-based company moves to cement its position as a key player in a new range of cancer therapies.